Tag Archives: Merck
By Pharm Exec | Published: September 16, 2014
Merck’s Keytruda, recently approved in the US to treat patients with advanced melanoma that have stopped responding to other cancer therapies, will soon face strong competition from Bristol-Myers Squibb’s (BMS) Opdivo, an analyst from research and consulting firm GlobalData has reported.
By Pharm Exec | Published: July 29, 2014
The launch of several drugs with “extraordinary blockbuster potential” will more than triple the acute coronary syndrome (ACS) treatment market, from $12.3 billion in 2013 to $43.4 billion by 2023, according to research and consulting firm GlobalData.
By William Looney | Published: May 5, 2014
Diabetes, it can be said, is one of the unpleasant side-effects of being human. Few other medical conditions are so heavily influenced by lifestyle and patterns of individual behavior, reinforced by a mix of economic, social and cultural factors. Nowhere do these form a more potent combination than in the Arab countries of the Middle East, […]
By Pharm Exec | Published: February 20, 2014
Four class representatives have been added to a class-action gender-discrimination employment suit originally filed last May against Merck & Co. in New Jersey.
By Marylyn Donahue | Published: November 20, 2013
The radical shift currently taking place in pharma marketing is all about partnering with patients rather than talking at them. In other words, pharma and patients are becoming friends who can help their “partners” educate, design a diet plan, increase disease awareness, and take you to the doctor…well, not quite yet.